[HTML][HTML] STING as an emerging therapeutic target for drug discovery: Perspectives from the global patent landscape
Abstract Background The STimulator of INterferon Genes (STING) plays an essential role in
the innate immune system by inducing the expression of type I interferons (IFNs) and …
the innate immune system by inducing the expression of type I interferons (IFNs) and …
LAG-3 antagonists by cancer treatment: a patent review
M Perez-Santos, M Anaya-Ruiz, J Cebada… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the downregulation of
the proliferation of antigen-specific lymphocytes. There is a great need to discover and …
the proliferation of antigen-specific lymphocytes. There is a great need to discover and …
OX40 agonists for cancer treatment: a patent review
J Cebada, M Perez-Santos, C Bandala… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction OX40 is an immune checkpoint in cancer and its presence in cancer is a good
prognosis, making it a highly relevant target for the development of new immunotherapies …
prognosis, making it a highly relevant target for the development of new immunotherapies …
Research and development of anti-Parkinson's drugs: an analysis from the perspective of technology flows measured by patent citations
Introduction: By 2020, nearly one million people will live with Parkinson's disease (PD) in the
US This disorder has a significant impact on patients' quality of life and is a burden on …
US This disorder has a significant impact on patients' quality of life and is a burden on …
The development trends of antineoplastics targeting PD-1/PD-L1 based on scientometrics and patentometrics
T Zhang, J Chen, Y Lu, Z Ouyang - BioRxiv, 2020 - biorxiv.org
Background This paper aims to show the scientific research and technological development
trends of antineoplastics targeting PD-1/PD-L1 based on scientometrics and patentometrics …
trends of antineoplastics targeting PD-1/PD-L1 based on scientometrics and patentometrics …
[PDF][PDF] 传染性单核细胞增多症患儿外周血B 淋巴细胞中免疫抑制因子的表达及意义
谭艳芳， 黄小平， 姜涛， 欧阳文献， 唐莲， 李双杰 - 收藏, 2019 - cccm-em120.com
目的观察4 种免疫抑制因子[程序性死亡受体-1 (PD-1), 程序性死亡受体-1 配体(PD-L1),
细胞毒性T 淋巴细胞相关抗原-4 (CTLA-4), 含T 细胞免疫球蛋白和ITIM 结构域蛋白(TIGIT)] …
细胞毒性T 淋巴细胞相关抗原-4 (CTLA-4), 含T 细胞免疫球蛋白和ITIM 结构域蛋白(TIGIT)] …
[PDF][PDF] OX40 agonists for cancer treatment: a patent
J Cebada, M Perez-Santos, C Bandala, E Lara-Padilla… - 2020 - academia.edu
Introduction: OX40 is an immune checkpoint in cancer and its presence in cancer is a good
prognosis, making it a highly relevant target for the development of new immunotherapies …
prognosis, making it a highly relevant target for the development of new immunotherapies …